Syncona has committed £63.5m in a Series B financing of Resolution Therapeutics, a company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases. Syncona has invested an initial tranche of £22.0m, with investment of the full Series B commitment dependent upon the completion of key milestones. Alongside … Continue reading Syncona ploughs £63.5m into Resolution Therapeutics